<div>
  <ul>
    <li>
      <p>
        Mental health-focused biotechnology company Psyence Group has raised USD 1.4 million through a private placement with Cantheon Capital, an investment fund focused on biotechnology. This brings total funds raised to USD 4.6 million.&nbsp;
      </p>
    </li>
    <li>
      <p>
        The funds raised will be used to finance Psyence's clinical trial in Australia. which will be carried out with the help of
        <a href="https://sp-edge.com/updates/17235">
           Ingenu
        </a>
        , a Contract Research Organization (CRO) partner that was announced in March 2023. The funds will be used to design and conduct Psyence's Phase IIb clinical trial using a natural psilocybin drug candidate PEX010, in a palliative care environment.&nbsp;
      </p>
    </li>
    <li>
      <p>
        Psyence is a life science biotechnology company that specializes in natural psychedelics, particularly in palliative care and the treatment of psychological trauma. The company's Psyence Biomed Division works with natural psilocybin products for this purpose. Psyence has established one of the world's first commercial psilocybin mushroom cultivation and production facilities in South Africa, which is federally licensed. The company is focused on various fields such as mycology, neurology, palliative care, and drug development, and operates internationally with divisions including Psyence Production, Psyence Therapeutics, and Psyence Function. The company has a presence in several countries including Canada, the UK, the US, and Australia.
      </p>
    </li>
  </ul>
  <p>
  </p>
</div>


<div>
  <p>
    &nbsp;
    <a href="https://psyence.com/2023/03/23/psyence-group-announces-cantheon-capital-private-placement/">
      Company Press Release
    </a>
  </p>
  <p>
  </p>
</div>


Psychedelic Medicine

Psyence raises USD 1.4 million through Cantheon Capital private placement

Psyence partners with Ingenu to conduct trial in palliative care

Diamond Therapeutics receives FDA approval for clinical trial of low-dose psilocybin

Field Trip Health closes clinics in five locations

Filament Health receives FDA approval for clinical trial of PEX010

GH Research Q4 and full-year 2022 results miss EPS analyst expectation

Compass Pathways Q4 and full-year 2022 results miss revenue and EPS analyst expectations

Mydecine raises USD 0.7 million in the eighth tranche of common share subscription agreement

Transcend Therapeutics raises USD 40 million in Series A funding

PharmaDrug partners with PharmaTher to develop DMT Transdermal patch

Awakn Life Sciences expands its operations in Portugal

Numinus opens new clinical research site in Arizona

Freedom Biosciences secures investment from LongeVC

Reunion Neuroscience Inc provides clinical and business updates for Q3 2023

Cybin Inc. provides clinical and business updates for Q3 2023

Revive Therapeutics partners with PharmaTher to develop an MDMA microneedle patch

Irwin Naturals raises USD 60 million in a credit facility

TRIPP partners with Equa Health to develop mindfulness training experiences

Small Pharma reports financial and business update for Q3 2023; expands patent portfolio

Within Health raises USD 1.1 million in funding

Journey Clinical raises USD 8.5 million in Series A funding

Lobe Sciences provides corporate update with its plan for 2023

Numinus Wellness provides financial and business update for Q1 FY2023

Revive Therapeutics closes USD 4.3 million private placement

MindMed provides corporate update with its plan for 2023

Wesana Health receives USD 0.25 million via short-term loan

Gilgamesh Pharmaceuticals raises USD 39 million Series B

Tryp Therapeutics provides business update for FY2022

BetterLife raises USD 0.5 million in non-brokered private placement

PsyBio Therapeutics plans CAD 1 million in private placement

All Updates